Tarsus Pharmaceuticals, Inc. TARS
We take great care to ensure that the data presented and summarized in this overview for Tarsus Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TARS
View all-
Rtw Investments, LP New York, NY3.32MShares$133 Million2.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$131 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.61MShares$105 Million6.87% of portfolio
-
Jennison Associates LLC2.49MShares$100 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$98.6 Million8.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.23MShares$89.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.01MShares$80.8 Million0.01% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.87MShares$75.3 Million0.19% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.48MShares$59.6 Million2.67% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.4MShares$56.1 Million4.52% of portfolio
Latest Institutional Activity in TARS
Top Purchases
Top Sells
About TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Insider Transactions at TARS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
13,608
-27.05%
|
$544,320
$40.42 P/Share
|
|
Jun 16
2025
|
Jeffrey S Farrow Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,881
+35.66%
|
-
|
|
Jun 16
2025
|
Elizabeth Yeu Lin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,006
-11.56%
|
$41,246
$41.08 P/Share
|
|
Jun 13
2025
|
Elizabeth Yeu Lin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+27.8%
|
-
|
|
Jun 13
2025
|
Andrew D. Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+16.71%
|
-
|
|
Jun 13
2025
|
Bhaskar Chaudhuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+27.8%
|
-
|
|
Jun 13
2025
|
William J Phd Link Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+1.93%
|
-
|
|
Jun 13
2025
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+50.0%
|
-
|
|
Jun 13
2025
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+19.65%
|
-
|
|
Jun 09
2025
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,500
-26.9%
|
$752,500
$43.76 P/Share
|
|
Mar 24
2025
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
6,000
-0.72%
|
$300,000
$50.0 P/Share
|
|
Mar 20
2025
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,365
-4.92%
|
$168,250
$50.11 P/Share
|
|
Mar 20
2025
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
1,186
-5.02%
|
$59,300
$50.11 P/Share
|
|
Mar 20
2025
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Direct |
8,534
-13.73%
|
$426,700
$50.11 P/Share
|
|
Mar 20
2025
|
Dianne C. Whitfield Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
2,137
-4.41%
|
$106,850
$50.11 P/Share
|
|
Mar 20
2025
|
Bryan Wahl General Counsel |
SELL
Open market or private sale
|
Direct |
3,084
-5.63%
|
$154,200
$50.11 P/Share
|
|
Mar 20
2025
|
Seshadri Neervannan Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,435
-2.97%
|
$121,750
$50.11 P/Share
|
|
Mar 19
2025
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,557
-4.94%
|
$167,179
$47.4 P/Share
|
|
Mar 19
2025
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
1,254
-5.04%
|
$58,938
$47.4 P/Share
|
|
Mar 19
2025
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Direct |
8,551
-12.09%
|
$401,897
$47.4 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 196K shares |
|---|---|
| Other acquisition or disposition | 37.6K shares |
| Open market or private sale | 136K shares |
|---|---|
| Other acquisition or disposition | 74.9K shares |
| Bona fide gift | 6.02K shares |